Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial

• Autores principales: Kristian Reich (Autor), Lars Erik Kristensen (Autor), Saxon D. Smith (Autor), Phoebe Rich (Autor), Christophe Sapin (Autor), Soyi Liu Leage (Autor), Robert McKenzie (Autor), Christopher Schuster (Autor), Elisabeth Riedl (Autor), Melinda Gooderham (Autor)
• Formato: Libro
• Publicado: Mattioli1885, 2022-05-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Introduction: The randomised, open-label, assessor-blinded, parallel-group SPIRIT-H2H trial (NCT03151551) demonstrated superiority of ixekizumab over adalimumab in simultaneously achieving improvement in joint symptoms (American College of Rheumatology [ACR]50) and clearance of skin lesions (Psorias...